Neumora Therapeutics, Inc.

NMRA Nasdaq CIK: 0001885522

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 260 ARSENAL PLACE, SUITE 1, WATERTOWN, MA, 02472
Mailing Address 260 ARSENAL PLACE, SUITE 1, WATERTOWN, MA, 02472
Phone (857) 760-0900
Fiscal Year End 1231
EIN 844367680

Financial Overview

FY2025

Recent SEC Filings

Form Type Date Filed Document
SCHEDULE 13D/A Beneficial ownership amendment April 1, 2026 View on SEC
8-K Current report of material events March 30, 2026 View on SEC
10-K Annual financial report March 30, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 19, 2026 View on SEC
4 Insider stock transaction report February 19, 2026 View on SEC
4 Insider stock transaction report February 19, 2026 View on SEC
4 Insider stock transaction report February 19, 2026 View on SEC
4 Insider stock transaction report February 19, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 17, 2026 View on SEC
8-K Current report of material events February 11, 2026 View on SEC

Annual Reports

10-K March 30, 2026
  • High-stakes Phase 3 data for Navacaprant expected in Q2 2026.
  • Strong cash position of $450 million provides runway into late 2027.
View Analysis

Insider Trading

SELL 4 insiders 4 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.